2025
Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.
Yusufaly T, Roncali E, Brosch-Lenz J, Uribe C, Jha A, Currie G, Dutta J, El-Fakhri G, McMeekin H, Pandit-Taskar N, Schwartz J, Shi K, Strigari L, Zaidi H, Saboury B, Rahmim A. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories. Journal Of Nuclear Medicine 2025, jnumed.124.267927. PMID: 39947910, DOI: 10.2967/jnumed.124.267927.Peer-Reviewed Original ResearchRadiopharmaceutical therapyImage-based dosimetryPrediction of doseInternal dosimetryPersonalized treatment plansMetastatic diseaseDosimetryNuclear oncologyClinical outcomesNuclear medicineClinical endpointsTreatment planningOncology communityDose responseEtiological mechanismsTargeted deliveryRadiobiologyRadiotherapyMalignancyRadiationLong-termTherapyPharmacotherapyDoseRadiopharmacokineticsChapter 52 Obsessive–compulsive disorder
Abdallah S, Olfson E, Fernandez T. Chapter 52 Obsessive–compulsive disorder. 2025, 937-950. DOI: 10.1016/b978-0-443-19176-3.00011-x.ChaptersObsessive-compulsive disorderObsessive-compulsive disorder etiologiesCognitive behavioral therapySerotonin reuptake inhibitorsReuptake inhibitorsBehavioral therapyMedication augmentationNeuroanatomical alterationsNeurochemical imbalanceMedication trialsGenetic influencesImprove treatment outcomesEvidence-based therapeutic strategiesTreatment outcomesRobust clinical trialsDisordersClinical manifestationsTreatment optionsClinical trialsTherapeutic strategiesSerotoninMultifactorial naturePharmacotherapyNeuromodulationTrials
2024
Nanotechnology approaches to drug delivery for the treatment of ischemic stroke
Peng B, Mohammed F, Tang X, Liu J, Sheth K, Zhou J. Nanotechnology approaches to drug delivery for the treatment of ischemic stroke. Bioactive Materials 2024, 43: 145-161. PMID: 39386225, PMCID: PMC11462157, DOI: 10.1016/j.bioactmat.2024.09.016.Peer-Reviewed Original ResearchBlood-brain barrierClinical translationClinical trialsFDA-approved pharmacotherapiesReview therapeutic agentsIschemic strokeTherapeutic agentsEffective treatment optionDrug deliveryTreatment of ischemic strokePotential clinical translationGlobal public health concernImprove delivery efficiencyTreatment optionsTreatment strategiesIschemic brainPublic health concernStroke pharmacotherapyEngineered nanoparticlesStroke treatment strategiesDelivery efficiencyNanotechnological approachesDrugPharmacotherapyStrokePersonalized brain circuit scores identify clinically distinct biotypes in depression and anxiety
Tozzi L, Zhang X, Pines A, Olmsted A, Zhai E, Anene E, Chesnut M, Holt-Gosselin B, Chang S, Stetz P, Ramirez C, Hack L, Korgaonkar M, Wintermark M, Gotlib I, Ma J, Williams L. Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety. Nature Medicine 2024, 30: 2076-2087. PMID: 38886626, PMCID: PMC11271415, DOI: 10.1038/s41591-024-03057-9.Peer-Reviewed Original ResearchBehavioral therapyFunctional magnetic resonance imaging protocolTask-free functional connectivityHeterogeneity of depressionBrain circuit dysfunctionResponse to pharmacotherapyTheoretical taxonomyAttentional circuitsNeurobiological dysfunctionBehavioral performanceCircuit dysfunctionCognitive tasksSubcortical regionsFunctional connectivityTask-freeAnxietyDepressionTheory-drivenPharmacotherapyStratification of patientsMagnetic resonance imaging protocolScoresPsychiatryDysfunctionClinical carePanic Disorder
Khasnavis S, Asghar-Ali A. Panic Disorder. 2024, 291-297. DOI: 10.1007/978-3-031-55711-8_22.Peer-Reviewed Original ResearchPanic disorderTreatment of panic disorderCognitive behavioral therapyOlder adultsBehavioral therapyPsychiatric reviewPhysical sensationsOnset episodesYoung adultsTreatment strategiesDisordersAppropriate treatment strategyAdultsNeurological conditionsProspective trialsPanicPharmacotherapyPatient preferencesWeighing risksFearTreatmentThe Present and Future of the Clinical Use of Physiological Traits for the Treatment of Patients with OSA: A Narrative Review
Chu Y, Zinchuk A. The Present and Future of the Clinical Use of Physiological Traits for the Treatment of Patients with OSA: A Narrative Review. Journal Of Clinical Medicine 2024, 13: 1636. PMID: 38541862, PMCID: PMC10970765, DOI: 10.3390/jcm13061636.Peer-Reviewed Original ResearchObstructive sleep apneaObstructive sleep apnea traitsSleep apneaUpper airway collapseHypoglossal nerve stimulationPositive airway pressureTreatment of patientsImpact treatment responseOral appliancesAirway pressureTreatment responseNerve stimulationTherapy modalitiesClinical useHeterogeneous groupApneaNarrative reviewTherapyPrecision careTreatmentPhysiological factorsPatientsPharmacotherapyClinicModalitiesRecent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023
Havlik J, Wahid S, Teopiz K, McIntyre R, Krystal J, Rhee T. Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023. Current Psychiatry Reports 2024, 26: 176-213. PMID: 38386251, DOI: 10.1007/s11920-024-01494-4.Peer-Reviewed Original ResearchTreatment of treatment-resistant depressionTreatment-resistant depressionMedication discontinuation ratesTranscranial magnetic stimulationElectroconvulsive therapyPsychiatric approachApproach to treatmentAdjunctive pharmacotherapyIntervention approachesAdjunctive treatmentDiscontinuation ratesMagnetic stimulationGeneralizability resultsDepressionPharmacotherapyInclusion criteriaAntipsychoticsPsychotherapyNarrative reviewKetamine/esketamineSide effectsStudy inclusion criteriaRecent FindingsRecent evidenceDisordersBuprenorphineCorrigendum to “Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response” [Drug Alcohol Depend. 232 (2022) 109257]
Votaw V, Mann K, Kranzler H, Roos C, Nakovics H, Witkiewitz K. Corrigendum to “Examining a brief measure and observed cutoff scores to identify reward and relief drinking profiles: Psychometric properties and pharmacotherapy response” [Drug Alcohol Depend. 232 (2022) 109257]. Drug And Alcohol Dependence 2024, 255: 111095. PMID: 38238245, PMCID: PMC10926843, DOI: 10.1016/j.drugalcdep.2024.111095.Peer-Reviewed Original ResearchTen years of research on the treatments of internet gaming disorder: A scoping review and directions for future research
Dong G, Dai J, Potenza M. Ten years of research on the treatments of internet gaming disorder: A scoping review and directions for future research. Journal Of Behavioral Addictions 2024, 13: 51-65. PMID: 38183434, PMCID: PMC10988415, DOI: 10.1556/2006.2023.00071.Peer-Reviewed Original ResearchNon-invasive brain stimulationCognitive behavioral therapyTreatment strategiesTreatment studiesInternet gaming disorderMedication-based treatmentDifferent treatment strategiesStudies of treatmentTreatment of IGDFuture studiesBrain stimulationControl groupBehavioral therapyGaming disorderTreatmentDSM-5Sex differencesDisordersSummary of findingsCurrent studyEarly stagesPharmacotherapyTherapyStudyYearsThe impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies
Costa G, Nunes J, Heringer D, Anand A, De Aquino J. The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies. The American Journal Of Drug And Alcohol Abuse 2024, 50: 12-26. PMID: 38225727, DOI: 10.1080/00952990.2023.2287406.Peer-Reviewed Original ResearchConceptsNon-medical opioid useOpioid use disorderOpioid useCannabis useOpioid use disorder pharmacotherapyUse disorderImpact of cannabis useAverage follow-up timeFollow-up timeMeta-analysisEvidence of moderate heterogeneityImpact of cannabisPooled odds ratioOpioids non-medicallyRandom-effects modelMeta-analysis of longitudinal studiesCannabis abstinenceTreatment modalitiesOdds ratioModerate heterogeneityPharmacotherapyCannabisOpioidComprehensive searchPublication bias
2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original ResearchExplaining How Psychotherapy Affects the Brain Can Increase the Perceived Effectiveness of Psychotherapy: A Randomized Controlled Trial
Perricone A, Bitran A, Ahn W. Explaining How Psychotherapy Affects the Brain Can Increase the Perceived Effectiveness of Psychotherapy: A Randomized Controlled Trial. Behavior Therapy 2023, 55: 738-750. PMID: 38937047, DOI: 10.1016/j.beth.2023.10.003.Peer-Reviewed Original ResearchEffectiveness of psychotherapyEfficacy of psychotherapyControlled TrialsUnderlying biological mechanismsDepression casesMental disordersClinical settingIntervention control conditionInterventionPsychotherapy resultsBiological mechanismsTrialsBrainControl conditionDepressionCurrent studyPsychotherapyParticipantsPharmacotherapyCliniciansBaselineBiological explanationCombining Pharmacotherapy and Psychological Treatments for Obsessive-Compulsive Disorder
Tolin D, Sain K. Combining Pharmacotherapy and Psychological Treatments for Obsessive-Compulsive Disorder. 2023, 557-583. DOI: 10.1093/oxfordhb/9780190068752.013.21.Peer-Reviewed Original ResearchCognitive behavioral therapyObsessive-compulsive disorderD-cycloserineFirst-line monotherapyEffective monotherapyCombined therapyMedication monotherapyMonotherapyFirst treatmentSystematic reviewCBT monotherapyTherapyPsychological treatmentCompulsive disorderPharmacotherapyTreatmentMeta-analytic strategyBiological mechanismsDisordersEfficacyPlaceboMedicationsPatientsAnti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
Yan L, Streja E, Li Y, Rajeevan N, Rowneki M, Berry K, Hynes D, Cunningham F, Huang G, Aslan M, Ioannou G, Bajema K. Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023. JAMA Network Open 2023, 6: e2331249. PMID: 37651140, PMCID: PMC10472184, DOI: 10.1001/jamanetworkopen.2023.31249.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapyVeterans Health AdministrationVeterans Integrated Service NetworkSARS-CoV-2Higher Charlson Comorbidity Index scoresCharlson Comorbidity Index scoreNon-Hispanic veteransComorbidity Index scoreProportion of patientsSymptomatic COVID-19Multivariable logistic regressionCOVID-19 vaccinationCohort studyMedicare databaseVHA careUS veteransMAIN OUTCOMEMedical conditionsHispanic veteransPharmacotherapyHealth AdministrationIndex scoreCommunity careNonhospitalized personsWhite veteransConverging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder
Farokhnia M, Rentsch C, Chuong V, McGinn M, Elvig S, Douglass E, Gonzalez L, Sanfilippo J, Marchette R, Tunstall B, Fiellin D, Koob G, Justice A, Leggio L, Vendruscolo L. Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder. Alcohol 2023, 109: 83-84. DOI: 10.1016/j.alcohol.2023.03.071.Peer-Reviewed Original ResearchCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapySmoking-Cessation Pharmacotherapy After Stroke and Transient Ischemic Attack: A Get With The Guidelines-Stroke Analysis
Parikh N, Zhang C, Omran S, Restifo D, Carpenter M, Schwamm L, Kamel H. Smoking-Cessation Pharmacotherapy After Stroke and Transient Ischemic Attack: A Get With The Guidelines-Stroke Analysis. Stroke 2023, 54: e63-e65. PMID: 36727507, PMCID: PMC9992306, DOI: 10.1161/strokeaha.122.041532.Peer-Reviewed Original ResearchThe choroid plexus links innate immunity to CSF dysregulation in hydrocephalus
Robert S, Reeves B, Kiziltug E, Duy P, Karimy J, Mansuri M, Marlier A, Allington G, Greenberg A, DeSpenza T, Singh A, Zeng X, Mekbib K, Kundishora A, Nelson-Williams C, Hao L, Zhang J, Lam T, Wilson R, Butler W, Diluna M, Feinberg P, Schafer D, Movahedi K, Tannenbaum A, Koundal S, Chen X, Benveniste H, Limbrick D, Schiff S, Carter B, Gunel M, Simard J, Lifton R, Alper S, Delpire E, Kahle K. The choroid plexus links innate immunity to CSF dysregulation in hydrocephalus. Cell 2023, 186: 764-785.e21. PMID: 36803604, PMCID: PMC10069664, DOI: 10.1016/j.cell.2023.01.017.Peer-Reviewed Original ResearchConceptsPost-infectious hydrocephalusTLR4-dependent immune responseBlood-cerebrospinal fluid barrierSmall molecule pharmacotherapyCell cross talkPharmacological immunomodulationCytokine stormNeuroimmune disordersBrain infectionDrug treatmentImmune responseAcquired hydrocephalusHydrocephalus modelChoroid plexusFluid barrierHydrocephalusEpithelial cellsCSFMulti-omics investigationsCross talkHypersecretionHemorrhagePharmacotherapyImmunomodulationPlexusClinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States
Desai N, Sutton M, Xie J, Fine J, Gao W, Owens A, Naidu S. Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal Of Cardiology 2023, 192: 16-23. PMID: 36709525, DOI: 10.1016/j.amjcard.2022.12.030.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyIndex dateCardiovascular eventsIncidence rateSymptomatic obstructive hypertrophic cardiomyopathyAtrial fibrillation/flutterCommon cardiovascular eventMonths continuous eligibilityHealthcare resource utilizationMedicare Supplemental databasesIBM MarketScan CommercialEligible patientsDiagnosis dateMarketScan CommercialClinical outcomesContinuous eligibilityTreatment optionsCumulative riskPatientsResource utilizationPharmacotherapyCardiomyopathyDisease
2022
Medical Therapy with Antimuscarinics and ß3-Agonists
Goodridge S, Rickey L. Medical Therapy with Antimuscarinics and ß3-Agonists. 2022, 147-164. DOI: 10.1007/978-3-030-84352-6_8.Peer-Reviewed Original ResearchOveractive bladderManagement of OABTreatment of OABMedical therapy optionsSecond-line therapyFirst-line treatmentSide effect profileBeta-3 agonistQuality of lifeMedical therapyEffect profileTherapy optionsDrug classesComparative efficacyBehavioral modificationAntimuscarinicsBladderTherapyEfficacyTreatmentPharmacotherapyPatientsAgonistsLarge subsetProgression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply